In our model of BT-474.r2T breast cancer cells, the initial characterization of the molecular alterations found in the HER family proteins as a consequence of the generation of resistance to trastuzumab revealed increased levels of some of the receptors, as well as activation (by phosphorylation) of most of them, including HER2. Here, ERBB2 is linked to breast cancer.